EXAI BIO
Exai Bio is a next-generation liquid biospy company. Exai bio proprietary RNA and artificial intelligence-based liquid biopsy platform deliver clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.
EXAI BIO
Industry:
Biotechnology Health Diagnostics
Founded:
2021-01-01
Address:
Palo Alto, California, United States
Country:
United States
Website Url:
http://www.exai.bio
Total Employee:
11+
Status:
Active
Total Funding:
67.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics Google Tag Manager Domain Not Resolving Global Site Tag Amazon IPv6
Similar Organizations
Injectsense
Monitoring therapy effectiveness (glaucoma) through miniaturized, autonomous in-vivo sensing and data uploading to cloud database.
Current Employees Featured
Founder
Investors List
Section 32
Section 32 investment in Series A - Exai Bio
Casdin Capital
Casdin Capital investment in Series A - Exai Bio
Two Sigma Ventures
Two Sigma Ventures investment in Series A - Exai Bio
Official Site Inspections
http://www.exai.bio Semrush global rank: 5.74 M Semrush visits lastest month: 1.46 K
- Host name: aacb0a264e514dd48.awsglobalaccelerator.com
- IP address: 75.2.70.75
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Exai Bio"
Exai Bio - Crunchbase Company Profile & Funding
Dec 9, 2021 Organization. Exai Bio . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. Exai Bio is an orphan non-coding …See details»
Leadership | Exai
Exai Bio Inc. 3350 west bayshore road palo alto, california 94303. quick links. Our advantage. Leadership. ... By clicking "Accept All", you are agreeing to store cookies on your device to enhance your experience and help Exai's …See details»
Exai Bio Company Profile 2024: Valuation, Funding
Exai Bio General Information Description. Developer of a liquid biopsy platform designed to accurately diagnose cancer and inform personalized care treatments. The company's platform measures cell-free RNA profiles, analyzing them …See details»
Exai Bio - LinkedIn
Exai Bio is a next-generation liquid biopsy company. Our mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized and targeted way, and ...See details»
Exai Bio Secures $67.5 Million Series A
“Exai Bio is the first company founded to explore the important role of oncRNA in early and more accurate cancer detection and its important impact on improved patient outcomes and health economics,” said Patrick Arensdorf, chief …See details»
Exai Bio Secures $67.5 Million Series A Financing to …
Dec 9, 2021 Exai Bio announces $67.5M Series A to advance its RNA-based liquid biopsy platform; Announces supporting data at San Antonio Breast Cancer Conference ... charitable organization established as ...See details»
Exai Bio Demonstrates Its Unique RNA-based Liquid Biopsy …
Apr 12, 2022 Exai Bio is focused on early cancer detection for multiple types of cancer, including the 28 cancer types explored in the TCGA cohort, for which it has identified a proprietary …See details»
Exai Bio’s RNA- and AI-based Liquid Biopsy Platform Detects Early …
PALO ALTO, Calif., December 06, 2023--Exai Bio today announced new data demonstrating that its novel RNA-based and AI-driven liquid biopsy platform can detect breast cancer at the …See details»
Exai Bio - Funding, Financials, Valuation & Investors - Crunchbase
Exai Bio is an orphan non-coding RNAs and AI-based liquid biopsy company. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. Resources. Pricing. …See details»
Our Advantage | Exai
Exai has shown that oncRNA patterns can be used to detect several types and subtypes of cancer, predict cancer tissue-of-origin and detect cancer at the earliest stages. In a study using blood samples from patients with breast …See details»
Exai Bio - Contacts, Employees, Board Members, Advisors & Alumni
Exai Bio has 3 current employee profiles, including Chief Executive Officer David J. Daly. David J. Daly Chief Executive Officer Nelson Lee Chief Administrative OfficerSee details»
Exai Bio Announces Publication in Nature Communications …
PALO ALTO, Calif., November 21, 2024--Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced a peer-reviewed publication about its …See details»
Exai Bio Presents New Multi-Cancer Early Detection Data at the …
Exai Bio today announced new data from a 3,300 subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, …See details»
Exai Bio’s RNA- and AI-based Liquid Biopsy Platform Detects Early …
Dec 8, 2023 Exai Bio today announced new data demonstrating that its novel RNA-based and AI-driven liquid biopsy platform can detect breast cancer at the earliest stages and the …See details»
Partnerships | Exai
Organization. your role. tell us more. interests. Learn about our clinical studies Interest in future studies and products Learn more about our RNA technology. ... Exai Bio Inc. 3350 west …See details»
New Multi-Cancer Early Detection Data Presented at ASCO 2023
Jun 6, 2023 Exai Bio announced new data from a 3,300-subject study demonstrating that its novel RNA- and AI-based platform can detect multiple cancer types at the earliest stages …See details»
Exai Bio Announces Publication in Nature Communications …
Nov 21, 2024 Exai Bio is a next-generation liquid biopsy company. Its mission is to enable a world where cancer can be detected early, diagnosed accurately, treated in a personalized …See details»
Exai Bio Secures $67.5 Million Series A Financing to Advance
Dec 9, 2021 SAN FRANCISCO--(BUSINESS WIRE)-- Exai Bio, a next-generation liquid biopsy company, today announced it has raised a $67.5 million Series A financing to accelerate …See details»
Exai Bio Announces Publication in Nature Communications …
Nov 21, 2024 Exai Bio, a next-generation oncRNA- and generative AI-based liquid biopsy company, today announced a peer-reviewed publication about its generative AI model in …See details»